Nurix Therapeutics, Inc. Stock Price, News & Analysis

Nurix Therapeutics (Nasdaq: NRIX) reported its fourth quarter and fiscal year 2021 financial results, revealing significant advancements in its drug development pipeline with four candidates entering clinical development. The company ended the year with $433 million in cash and investments, up from $372 million in 2020. Collaborations with Sanofi and Gilead boosted revenue to $29.8 million for the year. However, net losses increased to $117.2 million, or $2.73 per share. Positive early clinical data were reported for NX-2127, highlighting its potential in treating B-cell malignancies.

Nurix Therapeutics (NRIX), a biopharmaceutical company, has advanced four clinical programs from its DELigase platform into clinical development. In 2021, significant milestones were achieved, including the demonstration of targeted protein degradation in patients with hematologic malignancies. For 2022, Nurix anticipates data presentations from all four programs, including NX-2127, NX-5948, NX-1607, and DeTIL-0255. Additionally, a public offering raised approximately $150 million, aiding further development. Collaborations with Sanofi and new initiatives in pediatric cancers are also highlighted.

Nurix Therapeutics (Nasdaq: NRIX) announces that Arthur T. Sands, M.D., Ph.D., will present the company's performance and goals at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 5:15 PM ET. The presentation will be available via a live webcast on Nurix's website and archived for 30 days post-event. Nurix focuses on developing targeted protein modulation therapies for cancer, leveraging its DELigase platform and expertise in E3 ligases to create novel drug candidates.

Nurix Therapeutics (NRIX) announced that the U.K. Medicines & Healthcare products Regulatory Agency granted Clinical Trial Authorization (CTA) for NX-5948, a selective degrader of Bruton’s tyrosine kinase (BTK). The Phase 1 trial for patients with relapsed B-cell malignancies is set to begin in early 2022. Preclinical studies revealed NX-5948’s effectiveness, showing significant tumor reduction and improved survival rates in models. Notably, it crossed the blood-brain barrier, positioning it for dual development in oncology and autoimmune diseases.

Nurix Therapeutics announced FDA clearance for its DeTIL-0255 Investigational New Drug Application, paving the way for a Phase 1 clinical trial expected to begin by year-end 2021. DeTIL-0255 is an autologous T cell therapy targeting advanced malignancies, particularly gynecological cancers. The trial aims to enroll up to 50 patients, focusing on recurrent or persistent cancers. This advancement follows the company's success with its oral CBL-B inhibitor, NX-1607, currently in Phase 1a trials.

Nurix Therapeutics (Nasdaq: NRIX) announced preclinical findings for its CBL-B inhibitor, NX-0255, that enhance T cell expansion and quality for tumor infiltrating lymphocyte (TIL) therapy. Results show DeTIL-0255, a drug-enhanced TIL candidate, generated significant increases in T cell expansion (p<0.001), reduced exhaustion markers (p<0.05), and improved cytotoxicity (p<0.001). The findings support advancing DeTIL-0255 into clinical trials, with plans for a Phase 1 trial targeting patients with gynecological tumors. Additionally, Michael T. Lotze, the company's CCO, received the 2021 SITC Lifetime Achievement Award.

Nurix Therapeutics (Nasdaq: NRIX) has announced that its CEO, Arthur T. Sands, M.D., Ph.D., will participate in two upcoming virtual healthcare conferences in November. The events include the Stifel 2021 Virtual Healthcare Conference on November 16, from 3:20 to 3:50 PM EST, and the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, from 11:30 to 11:55 AM EST. These discussions will be available via live webcast through the Investors section of the Nurix website, with archived copies accessible for 30 days following each event.

Nurix Therapeutics (NRIX) has reported initial data on its lead drug candidate, NX-2127, demonstrating over 90% degradation of Bruton’s tyrosine kinase (BTK) in patients with relapsed B-cell malignancies. This achievement marks a significant milestone in the targeted protein degradation approach for treating cancers. The phase 1a study reported promising results, with patients showing sustained BTK suppression and a notable partial response in a CLL patient resistant to traditional therapies. The company plans to advance to the expansion phase in 2022.

Nurix Therapeutics (NRIX) is set to present initial pharmacokinetic and pharmacodynamic data from its first-in-human, Phase 1 dose-escalation trial of NX-2127 for treating relapsed or refractory B-cell malignancies at the 4th Annual Targeted Protein Degradation Summit. The presentation occurs on October 27, 2021, at 11:45 a.m. ET, led by CEO Arthur T. Sands. A conference call for further discussion will precede the presentation at 8:30 a.m. ET. NX-2127 is an orally bioavailable degrader of BTK, aimed at addressing treatment resistance in affected patients.